[High-dose CDDP therapy using a balloon-occluded arterial infusion (BOAI) in recurrent ovarian cancer].
An intraarterial high-dose CDDP, using a balloon catheter, has been infused into five patients with a recurrent ovarian cancer. The dose of CDDP was 150 mg-200 mg/body. Two patients experienced a partial tumor regression, whereas three showed no change. With regard to the toxicity, the NAG index (NAG activity/urinary creatinine) rose markedly in all patients, but toxicity was almost similar to that seen from a systemic administration. No significant catheter complication occurred.
Suzumori
K
K
Dept. of Obstet. & Gyne., Nagoya City Univ. School of Med.
Yasui
Y
Y
Yagami
Y
Y
Mimura
M
M
Banno
T
T
Nakamura
T
T
D000328:Adult; D001806:Blood Urea Nitrogen; D002945:Cisplatin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D003537:Cystadenoma / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D007677:Kidney Function Tests; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology
D002945:Cisplatin